Skip to main content
16 August 2026
14 August 2026

Atrium Therapeutics Advances RNA Cardiovascular Collaboration with BMSd

Atrium Therapeutics, Inc., a biopharmaceutical company dedicated to delivering RNA therapeutics to the heart, announced it has earned another $15 million milestone payment from Bristol Myers Squibb based on the successful delivery of a lead compound targeting an undisclosed cardiology indication under the Company's on…

14 August 2026

Xcellon Biologics Expands CRDMO Footprint with GMP Facility Acquisition

Xcellon Biologics, a U.S.-based Contract Research, Development and Manufacturing Organization (CRDMO) specializing in bioconjugates and complex biologics, announced that it has signed a definitive agreement to acquire the GMP biologics manufacturing facility from NextCure, Inc. The acquisition marks a transformational…

13 August 2026

Thermo Fisher Completes $1.075B Sale of Microbiology Business

Thermo Fisher Scientific Inc, the world leader in serving science, announced that it has completed the sale of its microbiology business to Astorg, a leading pan-European private equity firm, for consideration of approximately $1.075 billion, consisting of cash and a $50 million seller note. The microbiology business…

11 August 2026

Jazz Pharma to Acquire Actio Biosciences in $1.32B Deal

Jazz Pharmaceuticals plc and Actio Biosciences, Inc. announced the companies have entered into a definitive agreement for Jazz to acquire privately-held Actio Biosciences for $820 million upfront and up to $500 million in contingent consideration. Actio Biosciences' lead clinical asset is ABS-1230, a novel, first-in-…

06 August 2026

Evotec, Odyssey Launch AI-Driven Autoimmune Drug Discovery Collaboration

Evotec SE  announced that it has entered a strategic R&D collaboration with Odyssey Therapeutics, Inc. to discover potential new treatments in autoimmune and inflammatory diseases. Under the agreement, Odyssey will leverage Evotec's integrated data-driven discovery platform, advanced screening capabilities and AI…

04 August 2026

Codis Completes Acquisition of Catalent's UK Facility

Codis, a global contract development and manufacturing organization (CDMO) specializing in spray drying, amorphous solid dispersions (ASDs), and advanced particle engineering solutions, announced the successful closing of its acquisition of Catalent's Nottingham, UK facility. With the transaction now complete, Codis …

04 August 2026

Genprex Strengthens Oncology Pipeline with Roche Diagnostics Collaboration

Genprex, Inc. a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced its collaboration with Roche Diagnostics to validate biomarkers for patient selection in clinical trials for non-small cell lung cancer (NSCLC). Building on promising precl…

Page 1 of 37